SITC 2021 | Challenges of dual-targeted CAR T-cell therapy
Crystal Mackall
• 12 Nov 2021
Crystal Mackall, MD, Stanford University, Stanford, CA, outlines the main obstacles in developing dual-targeted chimeric antigen receptor (CAR) T-cell therapies by producing two mono-specific CAR T-cell populations. To begin with, this strategy is considerably more expensive and more difficult to manufacture than one monospecific CAR T-cell. In addition, engineering two CAR T-cell populations can lead to a competition for nutrients which can reduce the long-lived potential of both cell products. Alternative strategies include cotransduction, which consists of simultaneously engineering T-cells with two CAR constructs. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
